Cargando…

Integrative Hematology: State of the Art

Blood cancers are a group of diseases with thus far frequently poor prognosis. Although many new drugs, including target therapies, have been developed in recent years, there is still a need to expand our therapeutic armamentarium to better deal with these diseases. Integrative hematology was concei...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreazzoli, Francesca, Bonucci, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864076/
https://www.ncbi.nlm.nih.gov/pubmed/36675247
http://dx.doi.org/10.3390/ijms24021732
_version_ 1784875493485445120
author Andreazzoli, Francesca
Bonucci, Massimo
author_facet Andreazzoli, Francesca
Bonucci, Massimo
author_sort Andreazzoli, Francesca
collection PubMed
description Blood cancers are a group of diseases with thus far frequently poor prognosis. Although many new drugs, including target therapies, have been developed in recent years, there is still a need to expand our therapeutic armamentarium to better deal with these diseases. Integrative hematology was conceived as a discipline that enriches the patient’s therapeutic possibilities with the use of supplements, vitamins and a nutritional approach aiming at improving the response to therapies and the clinical outcome. We will analyze the substances that have proved most useful in preclinical and clinical studies in some of the most frequent blood diseases or in those where these studies are more numerous; the importance of the nutritional approach and the role of the intestinal microbiota will also be emphasized.
format Online
Article
Text
id pubmed-9864076
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98640762023-01-22 Integrative Hematology: State of the Art Andreazzoli, Francesca Bonucci, Massimo Int J Mol Sci Review Blood cancers are a group of diseases with thus far frequently poor prognosis. Although many new drugs, including target therapies, have been developed in recent years, there is still a need to expand our therapeutic armamentarium to better deal with these diseases. Integrative hematology was conceived as a discipline that enriches the patient’s therapeutic possibilities with the use of supplements, vitamins and a nutritional approach aiming at improving the response to therapies and the clinical outcome. We will analyze the substances that have proved most useful in preclinical and clinical studies in some of the most frequent blood diseases or in those where these studies are more numerous; the importance of the nutritional approach and the role of the intestinal microbiota will also be emphasized. MDPI 2023-01-15 /pmc/articles/PMC9864076/ /pubmed/36675247 http://dx.doi.org/10.3390/ijms24021732 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Andreazzoli, Francesca
Bonucci, Massimo
Integrative Hematology: State of the Art
title Integrative Hematology: State of the Art
title_full Integrative Hematology: State of the Art
title_fullStr Integrative Hematology: State of the Art
title_full_unstemmed Integrative Hematology: State of the Art
title_short Integrative Hematology: State of the Art
title_sort integrative hematology: state of the art
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864076/
https://www.ncbi.nlm.nih.gov/pubmed/36675247
http://dx.doi.org/10.3390/ijms24021732
work_keys_str_mv AT andreazzolifrancesca integrativehematologystateoftheart
AT bonuccimassimo integrativehematologystateoftheart